{"entity":{"id":"nct06311214","kind":"trial","name":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","aka":[],"tldr":"An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.","summary":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial). ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06311214","url":"https://clinicaltrials.gov/study/NCT06311214"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-09-04: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06311214","phase":"2","setting":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","sponsor":"National Cancer Institute (NCI)","started":"2025-03-18","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06311214/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}